Please login to the form below

Not currently logged in


This page shows the latest neuroendocrine news and features for those working in and with pharma, biotech and healthcare.

Chi-Med goes for third IPO in Hong Kong

Chi-Med goes for third IPO in Hong Kong

It is in a clutch of trials as a monotherapy in neuroendocrine tumours and biliary tract cancer, as well as in combination with Shanghai Junshi Biosciences’ PD-1 checkpoint inhibitor Tuoyi

Latest news

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    The drug treats the hormonal disorder acromegaly and neuroendocrine tumours (NETs), a rare form of cancer.

  • Pharma deals during September 2013 Pharma deals during September 2013

    from Camarus, paying an undisclosed milestone included in their $700 million deal signed two years ago for the indications acromegaly and neuroendocrine tumours.

  • Pharma deals during February 2013 Pharma deals during February 2013

    Roche has acquired an exclusive licence from Chiasma for Octreolin (in phase III), an orphan designated oral treatment in US for acromegaly with a neuroendocrine tumour indication to follow.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...